

DO NOT ENTER: /CMW/ 11/03/2008

Amendment in Response to Final Office Action mailed June 19, 2008  
U.S. Patent Application No. 10/786,223

**In the Claims:**

1. (withdrawn) A method of inhibiting interleukin-1 alpha (IL-1 $\alpha$ ) release from a cell, said method comprising administering an effective amount of an IL-1 $\alpha$  release inhibitor to said cell, thereby inhibiting IL-1 $\alpha$  release from said cell.

2. (withdrawn) The method of claim 1, wherein said release is stress-induced, and further wherein said IL-1 $\alpha$  release inhibitor is selected from the group consisting of a copper chelator and a S100A13, or a fragment thereof.

3. (withdrawn) The method of claim 3, wherein said S100A13 fragment is a S100A13 $\Delta$ BR truncated protein.

4. (withdrawn) The method of claim 4, wherein said copper chelator is tretrathiomolybdate (TTM).

5. (withdrawn) A method of treating a condition mediated by stress-induced release of IL-1 $\alpha$  from a cell, said method comprising administering an effective amount of a copper chelator to said cell, thereby treating said condition.

6. (Currently amended) A method of inhibiting neointima formation following vessel injury in a mammal, said method comprising inhibiting the interaction of IL-1 $\alpha$  with S100A13 by administering to said mammal an IL-1 $\alpha$  release inhibiting amount of a copper chelator, thereby inhibiting said neointima formation, wherein said IL-1 $\alpha$  release is non-traditional IL-1 $\alpha$  release.

7. (Canceled)

8. (Canceled)